Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cho

Showing results (271-280 of 299) with videos related to

Pageof 30
Sort By:
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Discovery of a Novel sp<sup>3</sup>‑Rich M<sub>1</sub> Positive Allosteric Modulators (PAMs) Chemotype via Scaffold HoppingJoseph D Bungard, Paul Spearing, Yu Nishio, et al.
Biological Psychiatry|November 13, 2012
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activityJerri M Rook, Meredith J Noetzel, Wendy A Pouliot, et al.
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
Molecular Cancer Therapeutics|August 20, 2021
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging AgentsJessica Gartrell, Marcia Mellado-Largarde, Michael R Clay, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2018
Corrigendum to "Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]James C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M<sub>1</sub> Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogsMichael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Pageof 30

Showing results (271-280 of 299) with videos related to

Sort By:
Pageof 30
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Discovery of a Novel sp<sup>3</sup>‑Rich M<sub>1</sub> Positive Allosteric Modulators (PAMs) Chemotype via Scaffold HoppingJoseph D Bungard, Paul Spearing, Yu Nishio, et al.
Biological Psychiatry|November 13, 2012
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activityJerri M Rook, Meredith J Noetzel, Wendy A Pouliot, et al.
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
Molecular Cancer Therapeutics|August 20, 2021
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging AgentsJessica Gartrell, Marcia Mellado-Largarde, Michael R Clay, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2018
Corrigendum to "Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]James C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M<sub>1</sub> Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogsMichael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Pageof 30